Pulse Biosciences, Inc. (PLSE)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-04) · 99.1 | ||
| 10-K/A | FY-2025 | |||
| 10-KLatest | FY-2025 | 8-K (2026-02-19) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-03-28) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-30) · 99.1 · 99.2 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 · 99.2 | 8-K (2024-07-15) | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-28) · 99.1 · 99.2 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-13) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | — |
|
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (deficit) | ||
| Condensed Consolidated Statements of Stockholders' Equity (dificit) (unaudited) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity (deficit) (P) | ||
| Condensed Consolidated Statements of Stockholders' Equity (unaudited) (P) | — |
|
| Notes | ||
| Award Timing Disclosure | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Note 1 | ||
| Note 1 - Description of The Business | — |
|
| Note 10 | ||
| Note 10 - Subsequent Events | — |
|
| Note 11 | ||
| Note 12 | ||
| Note 13 | ||
| Note 14 | — |
|
| Note 15 | — |
|
| Note 16 | — |
|
| Note 17 | — |
|
| Note 2 | ||
| Note 2 - Summary of Significant Accounting Policies | — |
|
| Note 3 | ||
| Note 3 - Fair Value Measurement | — |
|
| Note 4 | ||
| Note 4 - Accrued Liabilities | — |
|
| Note 5 | ||
| Note 5 - Stockholders' Equity | — |
|
| Note 6 | ||
| Note 6 - Stock-based Compensation | — |
|
| Note 7 | ||
| Note 7 - Net Loss Per Share | — |
|
| Note 8 | ||
| Note 8 - Segment Reporting | — |
|
| Note 8- Segment Reporting | — |
|
| Note 9 | ||
| Note 9 - Related Party Transactions | — |
|